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The Effect of Isoflavones on Bone Mass and Bone
Remodelling Markers in Postmenopausal Women
Aim: Recently, isoflavones have attracted attention for their potential roles in the prevention and treatment
of estrogen-related osteoporosis. However, the optimal dosage and the components responsible for the
favorable effects of isoflavones on bone in humans are still unclear. This study aims to investigate the effect
of low-dose isoflavones on bone mineral density (BMD) and on biochemical markers of bone turnover in early
postmenopausal women.
Materials and Methods: Ninety participants between 42-59 years of age were randomly assigned to receive
twice a day either isoflavone tablet (n:45) that provided 29.8 mg genistein, 7.8 mg daidzein, and 2.4 mg
glycitein per tablet or placebo tablets (n:45) containing 250 mg starch. BMD was measured both in lumbar
spine and hip, and bone biomarkers of serum osteocalcin, serum alkaline phosphatase (ALP) and serum Cterminal telopeptide (CTX) were measured at baseline and after six months of therapy at the end of the study.
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Results: Isoflavone treatment after six months significantly increased BMD of L2-4 T score (+19%, p=0.000)
and Ward triangle T score (+20%, p=0.000); femur neck T score (+4%, p=0.06) was also increased but this
change did not reach a level of statistical significance. Serum CTX level (-25%, p=0.047) decreased in the
isoflavone group, while osteocalcin (-8.3%, p=0.23) and ALP levels (+ 4.5%, p=0.43) showed no change.
Conclusions: Isoflavone increases BMD of L2-4 and Ward triangle T scores at a dosage of 59.6 mg genistein
with 15.6 mg daidzein and reduces bone resorption in early postmenopausal women.
Key Words: Isoflavone, genistein, bone mineral density, osteocalcin, serum C-terminal telopeptides

Postmenopausal Kad›nlarda Isoflavonlar›n Kemik Kitle ve
Döngü Belirteçleri Üzerine Etkisi
Amaç: Son zamanlarda isoflavonlar östrojen iliﬂkili osteoporozun tedavi ve korunmas›ndaki potansiyel rolleri
nedeniyle dikkatleri üzerlerine çekmiﬂtir. Ancak, insanlarda isoflavonlar›n kemik üzerine hangi doz ve tipte en
uygun etkiyi gösterdi¤i hala tam olarak aç›k de¤ildir. Bu çal›ﬂmada erken postmenapozal kad›nlarda düﬂük doz
isoflavonlar›n kemik mineral yo¤unlu¤u ve kemik döngüsünün biyokimyasal belirteçleri üzerine olan etkileri
araﬂt›r›ld›.
Yöntemler: Yaﬂlar› 42-59 aras›nda de¤iﬂen 90 hasta günde 2 kez, içerisinde 29.8 mg genistein, 7.8 mg
daidzein ve 2.4 mg glycitein bulunan isoflavon (n: 45) tabletleri veya içerisinde 250 mg niﬂasta bulunan
tabletleri (n: 45) alacak ﬂekilde rastgele belirlendi. Lomber omur ve kalça kemik mineral yo¤unlu¤u ile serum
osteokalsin, serum alkalen fosfataz (ALP) ve serum C terminal telopeptid (CTX) gibi kemik belirteçleri
çal›ﬂman›n baﬂlang›c›nda ve 6. ay›nda ölçüldü.
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Bulgular: ‹soflavon tedavisi 6 ay›n sonunda L2-4 T skoru (+ % 19, p=0.000) ve Wards triangle T skorunu
anlaml› olarak artt›rm›ﬂt›r, femur boynu T skorunda da art›ﬂ gözlenmiﬂtir fakat bu art›ﬂ istatistiksel olarak
anlaml› düzeye ulaﬂmam›ﬂt›r. ‹soflavon grubunda serum CTX (- % 25, p=0.047) düzeyi azal›rken, serum
osteokalsin (- % 8.3, p= 0.23) ve serum ALP düzeylerinde (+ % 4.5, p=0.43) bir de¤iﬂiklik olmam›ﬂt›r.
Sonuç: ‹soflavon, 59.6 mg genistein ile 15.6 mg daidzein dozlar›yla erken postmenopozal kad›nlarda L2-4 T
skoru ve Wards üçgeni T skorunu anlaml› ölçüde artt›r›rken kemik rezorpsiyonunu azaltmaktad›r.
Anahtar Sözcükler: ‹soflavon, genistein, kemik mineral yo¤unlu¤u, osteokalsin, serum C terminal
telopeptidler
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Introduction
Osteoporosis is now a major public health threat and its prevalence is expected to
rise dramatically in the coming decades. Estrogen deficiency is generally not listed as one
of the main risk factors for osteoporosis, but it is indirectly and strongly associated with
the many recognized risk factors: female gender, thin stature, advanced age,
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postmenopausal, amenorrhea and excessive alcohol
intake. Although attainment of peak bone mass is in the
late second decade, gradual bone loss occurs with aging
and this loss is accelerated in menopause. The loss may
initiate for the first time when menstrual cycles become
irregular in the perimenopause period. From 1.5 years
before to 1.5 years after menopause, spine bone mineral
density (BMD) has been shown to reduce 2.5% per year,
compared with a premenopausal loss rate of 0.13% per
year (1,2). Innumerable studies attest to the importance
of estrogen in bone remodeling, evident from the fact
that hormone therapy administered in a dose-dependent
manner effectively prevents bone loss in postmenopausal
women and reduces the incidence of fractures. However,
various reports about the adverse effects of hormone
therapy including increasing incidence of endometrial
disease, breast cancer and thromboembolic events (3-5)
will undoubtedly serve to increase the search for
alternative and natural strategies for menopausal
estrogen deficiency, including ways of managing the
prevention of osteoporosis with aging.
Recent studies have focused on natural alternatives,
such as phytoestrogens, that exert estrogen activity on
several tissues. In the past few years, isoflavones have
attracted attention for their potential roles in the
prevention and treatment of estrogen-related
osteoporosis (6). The chemical structures of the
phytoestrogens are similar to that of 17 β-estradiol, the
most potent naturally occurring estrogen. There are
three types of phytoestrogens, such as isoflavones,
coumestans and lignans, but only the first two types of
non-steroidal estrogen molecules own the skeletal effects.
The main isoflavones found in soy proteins and soy foods
are genistein and daidzein. Morabito et al. (7) showed
that genistein prevents bone loss caused by estrogen
deficiency. They are found in abundance in soybeans and
their derivative foods. Epidemiological studies suggest
that the low incidence of osteoporosis and heart diseases
caused by estrogen deficiency in Asian women is
attributable to their high intake of soy foods, compared
with American and Finnish women (8).
It has been demonstrated that genistein has a direct
effect on bone resorption and a stimulatory effect on
bone formation in tissue culture system in vitro (9,10).
Several animal studies have shown that soy protein or
isolated isoflavone-enriched soy extract supplementation
improves bone mass or other endpoints (11-13). Several
146
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human studies in postmenopausal women showed that
dietary supplement of phytoestrogens improved spine
BMD and reduced urinary excretion of bone resorption
markers (7,14,15). However, in contrast to these
studies, Kreijkamp-Kaspers et al. (16) reported that
isoflavones 99 mg/day did not show any effect on bone
health of postmenopausal women. The optimal dosage
and the components of isoflavones with respect to bone
health are still inconclusive.
The inconsistent and limited number of studies about
the effect of phytoestrogens on bone mass led us to
conduct a new prospective randomized study to provide
insight into this question. In this study, we aimed to
investigate the effects of isoflavones on bone mass and on
biochemical markers of bone turnover in postmenopausal
women.

Materials and Methods
In this study, 90 healthy postmenopausal women
were randomly selected from the Menopause Clinics of
the Department of Obstetrics and Gynecology of Fatih
University Medical School. This was a single center,
single-blind, placebo-controlled randomized study. The
volunteers received written and verbal information on the
purpose and the procedures of the study, and informed
written consent was obtained from all. Approval for this
study was obtained from the Institutional Review Board
of Fatih University.
Women were invited to participate if they had not
undergone surgically induced menopause, had not had a
menstrual period in the preceding year and had a follicle
stimulating hormone (FSH) level greater than 40 IU/L and
a serum estradiol (E2) level of 30 pg/ml or less. All
women had incapacitating hot flashes and other
climacteric symptoms.
Women with malignant disease, metabolic bone
diseases, current steroid treatment, cardiovascular,
hepatic, or renal disorders, coagulopathy, family history
of estrogen-dependent cancer, usage of hormone therapy
in the preceding year, or smoking habit of more than 10
cigarettes per day, and those receiving any medication
that could affect the skeleton or for the relief of
climacteric symptoms were excluded. The women were
not using statins, natural products with presumed
estrogenic activity, or drugs possibly affecting climacteric
symptoms or metabolism and absorption of
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phytoestrogens (e.g. antibiotics during the previous 3
months).
Participants were randomly assigned to receive twice
daily either isoflavone tablet (n:45) that provided 29.8
mg genistein, 7.8 mg daidzein, and 2.4 mg glycitein per
tablet (Isoflavin®; Mikrogen) or placebo tablets (n:45,
250 mg starch per tablet) of identical appearance.
Placebo pills were prepared with the same appearance by
the manufacturer of the isoflavone tablets. The
manufacturing company was not involved in the study
design and did not participate in any further part of the
trial. A block randomization was used in order to ensure
an equal number of patients in each group. Blocks were
numbered, all numbered papers were placed in a bag and
a staff who was blinded to the research protocol selected
the patients into the treatment groups.
Before initiation of therapy, a detailed personal and
family history was taken and all patients underwent
gynecologic and physical examination that included: Pap
smear, transvaginal ultrasonography (TVS), breast
examination and mammography, thyroid, renal and liver
function tests, and blood coagulation tests. Laboratory
tests including serum ALP, osteocalcin and CTX were
conducted before the initiation and after six months of
therapy. Fasting blood samples were collected at baseline
and at the sixth month of the therapy to measure bone
markers. Serum was separated by centrifugation and
serum aliquots kept frozen at -80 °C for subsequent
analysis. Serum ALP was measured by using the Metra kit
(Quidel Ltd, Oxford, United Kingdom; 35). Serum CTX
was
measured
with
electrochemiluminescence
immunoassay “ECLIA” kits (β-CrossLaps, English)
according to the manufacturer’s instruction. For the
analysis of osteocalcin, electrochemiluminescence
immunoassay “ECLIA” kits (N-MID, English) were used.
During the study, the women were encouraged to
lead normal lives, with no changes that might influence
the outcome in dietary habits, alcohol consumption, or
physical activity, which were all recorded by means of
questionnaires before initiation of study, at the third
month and at the end of the treatment period.
Participants were asked to complete a food-frequency
questionnaire (FFQ) at baseline at the third month and at
the end of the treatment period after having been given
verbal and written instructions on how to complete it.
Dietary calcium and vitamin D intakes were estimated
based on published food-composition tables by means of
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the FFQ. Women with a calcium intake of <500 mg/day
were advised to increase their intake. Dietary isoflavone
and lignan intake was assessed with the FFQ covering
habitual diet during the year preceding enrollment.
Patient compliance was reinforced by a physician by
means of a questionnaire that was completed by the
subjects before initiation of the study, at the third month
and at the end of the treatment period. All unfavorable
effects were accepted as adverse effects, such as breast
tenderness, vaginal bleeding, abdominal distention and
constipation.
BMDs of the anteroposterior lumbar spine (L2-L4),
femur neck and Ward triangle were measured by dualenergy X-ray absorptiometry (DXA) by one expert
technician at baseline and after six months of treatment.
The instrument was calibrated on a daily basis according
to the manufacturer’s instructions. All subjects were
subclassified by the World Health Organization (WHO)
criteria according to the lowest BMD in the lumbar spine
and the femoral neck as: normal controls (T-score >–1),
osteopenic (– 2.5 < T-score ≤ –1) and osteoporotic (Tscore ≤ – 2.5).
Statistical Analysis
Analysis of data was performed by SPSS package
program for Windows (11.5 SPSS Inc, Chicago, US).
Student’s t-test, paired-t test and chi-square test were
used when appropriate. A p value of <0.05 was accepted
as significant.
Based on the literature, we expected genistein to
reduce the markers of bone resorption. We considered a
20% decrease in six months as acceptable and power
analysis identified 90 patients (45 for each group) as the
total sample size required to detect the difference in
therapeutic success with a power of 80% at 5%
significance level.

Results
In total 90 subjects who met the inclusion criteria
were eligible for the study and received study medication.
The clinical data of the two randomized groups are shown
in Table 1. The 90 subjects were between 42-59 years of
age (1 to 6 years of menopause). All the groups had a
similar age, body mass index, menopause age and years
postmenopausal. Education levels of groups, food,
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Table 1. Baseline characteristics of participants in the trial.
Characteristics

Age (year)
2

Placebo
(n=45)

Isoflavone
(n=45)

51.0 ± 4.94

52 ± 5.43

BMI (kg/m )

27.4 ± 3.23

26.6 ± 3.04

Menopause age

46.71 ± 2.72

47.21 ± 3.76

Years after menopause

4.0 ± 1.66

3.3 ± 1.89

Tea consumption

3.28 ± 1.58

4.66 ± 3.29

Values are mean ± SD.
BMI: Body mass index.

vegetable, coffee, tea and soy-related food consumption,
exercise and smoking habits were similar.
During the 6 months period, there were 10 dropouts;
2 (4.4 %) dropouts in the isoflavone group, and eight
(17.7 %) dropouts in the placebo group, which left 43
and 37 participants, respectively, for the per protocol
analysis. In the isoflavone group one patient dropped out
because of being out of control and one patient for
personal reasons. In the placebo group two patients
dropped out because of taking the drugs irregularly and
6 patients because of lack of effect. Breast tenderness
occurred in 2 women during isoflavone treatment, and in
one women taking placebo-therapy.
In placebo group, baseline levels were as follows; L2L4 T score=-1.79 ± 0.47, Wards tringle T score= -1.19
± 0.98, femur neck T score = -1.38 ± 0.87, serum
osteocalcin = 22.92 ± 6.61, serum CTX=0.39 ± 0.17
and serum ALP=205.1 ± 43.9.
After 6 months in placebo group, L2-L4 T score= 1.97 ± 0.5, Wards tringle T score= -1.18 ± 0.95, femur
neck T score = -1.45 ± 0.99, serum osteocalcin= 25.47
± 4.65, serum CTX= 0.59 ± 0.26 and serum ALP=
207.1 ± 46 (Table 2).
In isoflavone group, baseline levels were; L2-L4 T
score= -1.76 ± 0.79, Wards tringle T score= -2.14 ±
0.77, Femur neck T score = -1.81± 0.81, serum
osteocalcin= 23.14 ± 5.67, serum CTX= 0.50 ± 0.21
and serum ALP= 211.5 ± 57.3.
After 6 months therapy in isoflavone group, L2-L4
score T score= -1.47 ± 0.89, Wards tringle T score= 1.69 ± 0.77, Femur neck T score=-1.51 ± 1.00, serum
osteocalcin 19.05 ± 6.17, serum CTX= 0.36 ± 0.15 and
serum ALP= 221.2 ± 56.4 (Table 2).
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At baseline L2–L4 T score (p= 0.879), serum
osteocalcin (p= 0.274), serum CTX (p= 0.159), serum
ALP (p= 0.708) and femur neck (p= 0.310) levels were
similar in both groups but Wards Triangle T score was
statistically lower in isoflavone group (p= 0.005).
After six months, Wards T score (p=0.104), femur
neck (p=0.07), serum CTX (p=0.035) and serum ALP
levels (p=0.418) were similar in both groups. However,
L2–L4 T score (p=0.04) was statistically increased in
isoflavone group and serum osteocalcin levels (p=0.012)
were also increased in placebo groups (Table 2).
Isoflavone treatment significantly increased BMD of
L2-4 T score and Wards triangle T score (L2-L4 T score
= + 19 %, p=0.000; Wards triangle T score = + 20 %,
p=0.000) but femur neck T score (+7 %, p=0.06) did
not change. Serum CTX levels after six months (CTX= 25 %, p=0.047) significantly reduced. However,
isoflavone treatment did not change serum osteocalcin
(Osteocalcin= -8.3 %, p=0.066) and ALP levels (ALP= +
4.5 %, p= 0.389) after six months (Table 2).
In placebo group, significantly decreased BMD scores
(L2-4 T score=-9.5 %, p=0.008), increased serum levels
of CTX (CTX= + 34.8 %, p=0.028) and osteocalcin
(osteocalcin= + 10.7 %, p=0.013) were observed.
Serum ALP levels (+ 0.9 %, p=0.867) did not change
(Table 2).
Discussion
In this study, we examined the effects of isoflavones
on BMD and biochemical markers of bone formation
(osteocalcin, ALP) and bone resorption (serum CTX). At
the sixth month of the treatment, we observed that
isoflavone treatment significantly reduced bone loss of
the lumbar spine and Wards triangle. In addition, it
reduced the bone resorption marker (CTX) in early
postmenopausal women, but bone formation markers
(osteocalcin, ALP) did not change.
Although in some studies daidzein was reported to be
more bioavailable (17) than genistein in rats and humans,
the anabolic effect of genistein on bone metabolism is
equal to that of daidzein (18). When daidzein is
hydroxylated, its chemical structure is similar to that of
genistein. The soy isoflavone tablets used in this study
have a higher proportion of genistein (29.8 mg) and
lower dose of daidzein (7.8 mg) and with this proportion
we observed a bone-sparing effect.
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Table 2. Effects of isoflavone and placebo on BMD and remodeling markers.

Variable

Baseline

After 6 months therapy

% change

P value for changes compared with
Baseline

Isoflavone-Placebo IsoflavoneBaseline
Placebo After

L2–L4 T score
g/cm2
Isoflavone
Placebo

-1.76 ± 0.79
-1.79 ± 0.47

-1.47 ± 0.89
-1.97 ± 0.5

+ 19
- 9.5

0.000
0.008

0. 879

0.040

Wards T score g/cm2
Isoflavone
Placebo

-2.14 ± 0.77
-1.19 ± 0.98

-1.69 ± 0.77
-1.18 ± 0.95

+ 20
- 0.3

0.000
0.954

0.005

0.104

Isoflavone
Placebo

- 1. 81 ± 0.81
-1.38 ± 0.87

-1.51 ± 1.00
-1.45 ± 0.99

+7
-3

0.06
0.35

0.310

0.07

Osteocalcin (ng/ml)
Isoflavone
Placebo

23.14 ± 5.67
22.92 ± 6.61

19.05 ± 6.17
25.47 ± 4.65

- 8.3
+ 10.7

0.066
0.013

0.274

0.012

Serum CTX (ng/ml)
Isoflavone
Placebo

0.50 ± 0.21
0.39 ± 0.17

0.36 ± 0.15
0.59 ± 0.26

- 25
+ 34.8

0.047
0.028

0.159

0.035

Serum ALP (U/L)
Isoflavone
Placebo

211.5 ± 57.3
205.1 ± 43.9

221.2 ± 56.4
207.1 ± 46.9

+ 4.5
+ 0.9

0. 389
0.867

0.708

0.418

Femur neck T score g/cm2

BMD: Bone mineral density. CTX: C-terminal telopeptide. ALP: Alkaline phosphatase.

The relationships between phytoestrogens and bone
tissue have been studied for less than a decade.
Therefore, the potential use of phytoestrogens to
preserve bone tissue and delay or prevent the onset of
osteoporosis in humans is only now being addressed by
researchers. The mechanism of the action of
phytoestrogens on bone metabolism are not yet clear and
still have to be elucidated. The beneficial effects of soy
isoflavones on bone tissue can result from either
increased bone formation by osteoblasts or decreased
bone resorption by osteoclasts. Several experimental
evidences suggest that the phytoestrogen effect on bone
formation may be a consequence, at least in part, of a
genomic and estrogen receptor-mediated effect involving
the activation or inhibition of the nuclear estrogen
receptor (19,20). Alternatively, a variety of non-genomic

mechanisms, including the inhibition of tyrosine kinase
(21), inhibition of topoisomerase II (22), or activation of
a putative membrane-bound receptor for estrogenic
molecules (23), have been proposed as the mechanisms
of action of genistein and other phytoestrogens. The
inhibition of osteoclastic bone resorption may result from
a direct action of phytoestrogens, presumably via nongenomic mechanisms, since mammalian osteoclasts
appear to lack estrogen receptors. Previous studies in cell
culture systems have shown that genistein has a direct
suppressive effect on osteoclasts by a number of possible
mechanisms, including induction of apoptosis through the
pathway of intracellular Ca+2 signalling, activation of
protein tyrosine phosphatase, and inhibition of cytokines
(24).
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Several human studies have shown that isoflavones
can reduce bone loss as measured by surrogate markers
of bone turnover and changes in BMD in postmenopausal
women. Morabito et al. (7) performed a randomized
double blind placebo controlled study to evaluate and
compare hormone therapy with the effect of the
phytoestrogen genistein on bone metabolism and BMD in
postmenopausal women. At the end of the treatment,
they showed that genistein increased BMD in the femur
and lumbar spine as effectively as hormone therapy, and
in addition administration of genistein markedly increased
markers of bone formation (serum bone-specific ALP and
osteocalcin) and reduced bone resorption in
postmenopausal women. In our study, in addition to
lumbar spine and femur neck BMD, we also studied Ward
triangle. After six months of therapy, only lumbar spine
and Ward triangle BMD were increased significantly;
femur neck BMD did not increase. Similarly, the bone
resorption marker (CTX) was decreased in our study but
bone formation markers (osteocalcin and ALP) showed no
change. The probable cause of the discrepancy between
Morabito’s results and ours may be the difference in the
periods of the studies. We used genistein for only six
months while Morabito et al. used it for one year. Like
our study, Mori et al. (25) reported that four-week
supplementation of isoflavone 40 mg a day as a tablet
does not influence the serum bone formation marker but
inhibited bone resorption in postmenopausal women.
Actually, if the objective is to monitor therapeutic
efficacy, it seems most rational to use a resorption
marker for drugs that act principally on osteoclasts, such
as estrogens or bisphosphonates (26). Although several
studies reported that isoflavone at 70-90 mg/day may be
needed for its bone-protective effect, we observed a
bone-protective effect of isoflavone at a dosage of 59.6
mg genistein and 15.6 mg daidzein. Mei et al. (27)
similarly reported a bone-protective effect of isoflavone
at 53.3 mg/day.
In another study, Chiechi et al. (28) randomized 187
healthy postmenopausal women into a soy-rich diet,
hormone replacement therapy and a control group, and
assessed bone biomarkers and BMD at baseline and after
six months of intervention. No significant differences
were demonstrated in either markers of bone resorption
(N-telopeptide-C and hydroxyproline) or forearm BMD
between those three groups. However, they studied only
forearm BMD, though it is well known that lumbar spine
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and femur neck are more sensitive than forearm BMD to
measurement in osteoporosis. More than half of the
subjects in the study group discontinued the study mainly
due to dislike of soy and difficulties in finding and cooking
foods. As a result of this high dropout rate, data from
only small number of subjects (n=24) was a disadvantage
of these studies.
In 2003, Chen et al. (15) reported a favorable effect
of soy isoflavone treatment on maintenance of hip bone
mineral content (BMC) but not on BMD in
postmenopausal women. The reasons for such different
responses of BMC and BMD to isoflavone
supplementation are unclear. The postmenopausal period
of the patients was long (within 10 years of natural
menopause) and this may have caused the different
responses of BMC and BMD to isoflavone
supplementation.
In our results, we clearly observed an increase in
lumbar spine BMD, but for hip, while Ward triangle BMD
demonstrated an increase, femur neck BMD did not
change. It is well known that many drugs used for
osteoporosis, such as estrogen and bisphosphonate, are
more effective on spinal bone than hip. The spine is
remodeled more rapidly than the hip, which contains a
higher proportion of cortical bone (29,30). The spine is
the area thought to be the most sensitive to estrogen
because of its higher content of trabecular bone. The soy
isoflavones used in this study have a higher proportion of
genistein and we thought that the bone-sparing effect of
isoflavone can be attributed to the similar effect of
estrogen. Hence, the undetectable effect of isoflavone
supplementation at the femur neck could be related to
this issue and the increase in Ward triangle BMD might be
accidental. The treatment period and the relatively small
number of patients might be accepted as the
disadvantages of our study. It is well known that bone
remodeling is a relatively slow process and six months of
treatment may not be adequate to predict the long-term
effects of isoflavones on bone mass. Normally, 6–18
months are needed to reach a new equilibrium with a
certain intervention (31,32). Hence, longer-term trials
would be required to evaluate the effects of isoflavones
on bone mass.
The unexpected results of our study were the
increases in both bone formation (osteocalcin) and bone
resorption (CTX) markers in the placebo group. This may
be explained by a new onset of osteoporosis in the
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placebo group. The increase in bone resorption
stimulated bone formation. However, this is a short study
with respect to bone and these findings need to be
checked via longer studies.
In conclusion, our results show that low dose of
isoflavone treatment improved BMD in the lumbar spine
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and reduced bone resorption in early postmenopausal
women. Nevertheless, before recommendation of this
low dose of isoflavones for the prevention of
postmenopausal osteoporosis, further studies are needed
to confirm the optimal dosages and treatment period.

References
1.

Riggs BL, Wahner HW, Melton LJ 3rd, Richelson LS, Judd HL,
Offord KP. Rates of bone loss in the appendicular and axial
skeletons of women. Evidence of substantial vertebral bone loss
before menopause. J Clin Invest 1986; 77(5): 1487-91.

2.

Slemenda C, Hui SL, Longcope C, Johnston CC. Sex steroids and
bone mass. A study of changes about the time of menopause. J
Clin Invest 1987; 80(5): 1261–9.

3.

Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE,
Stampfer MJ et al. The use of estrogens and progestins and the
risk of breast cancer in postmenopausal women. N Engl J Med
1995; 332(24): 1589-93.

4.

Boroditsky RS. Balancing safety and efficacy focus on endometrial
protection. J Reprod Med 2000; 45(3 Suppl): 273-84. Review.

5.

Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM. Risk of
hospital admission for idiopathic venous thromboembolism
among users of postmenopausal oestrogens. Lancet 1996;
348(9033): 981-3.

6.

7.

8.

Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J,
Nilsson S et al. Comparison of the ligand binding specificity and
transcript tissue distribution of estrogen receptors alpha and
beta. Endocrinology 1997; 138(3): 863-70.
Morabito N, Crisafulli A, Vergara C, Gaudio A, Lasco A, Frisina N
et al. Effects of genistein and hormone-replacement therapy on
bone loss in early postmenopausal women: a randomized doubleblind placebo-controlled study. J Bone Miner Res 2002; 17(10):
1904-12.
Adlercreutz H, Hamalainen E, Gorbach S, Goldin B. Dietary phytooestrogens and the menopause in Japan. Lancet 1992;
339(8803): 1233.

9.

Yamaguchi M, Gao YH. Inhibitory effect of genistein on bone
resorption in tissue culture. Biochem Pharmacol 1998; 55(1): 716.

10.

Yamaguchi M, Gao YH. Anabolic effect of genistein and genistin
on bone metabolism in the femoral-metaphyseal tissues of elderly
rats: the genistein effect is enhanced by zinc. Mol Cell Biochem.
1998; 178(1-2): 377-82.

11.

Anderson JJ, Garner SC. Phytoestrogens and bone. Baillieres Clin
Endocrinol Metab 1998; 12(4): 543-57. Review.

12.

Arjmandi BH, Alekel L, Hollis BW, Amin D, Stacewicz-Sapuntzakis
M, Guo P et al. Dietary soybean protein prevents bone loss in an
ovariectomized rat model of osteoporosis. J Nutr 1996; 126(1):
161-7.

13.

Arjmandi BH, Smith BJ. Soy isoflavones' osteoprotective role in
postmenopausal women: mechanism of action. J Nutr Biochem
2002; 13(3): 130-7.

14.

Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman JW
et al. Soy protein and isoflavones: their effects on blood lipids and
bone density in postmenopausal women. Am J Clin Nutr 1998;
68(6 Suppl): 1375S-9S.

15.

Chen YM, Ho SC, Lam SS, Ho SS, Woo JL. Soy isoflavones have a
favorable effect on bone loss in Chinese postmenopausal women
with lower bone mass: a double-blind, randomized, controlled
trial. J Clin Endocrinol Metab 2003; 88(10): 4740-7.

16.

Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman
A, Lampe JW et al. Effect of soy protein containing isoflavones on
cognitive function, bone mineral density, and plasma lipids in
postmenopausal women: a randomized controlled trial. JAMA
2004; 292(1): 65-74.

17.

Xu X, Wang HJ, Murphy PA, Cook L, Hendrich S. Daidzein is a
more bioavailable soymilk isoflavone than is genistein in adult
women. J Nutr 1994; 124: 825-32.

18.

Sugimoto E, Yamaguchi M. Stimulatory effect of daidzein in
osteoblastic MC3T3-E1 cells. Biochem Pharmacol 2000; 59(5):
471-5.

19.

Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T. Expression of
estrogen receptor beta in rat bone. Endocrinology 1997;
138(10): 4509-12.

20.

Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J,
Nilsson S et al. Comparison of the ligand binding specificity and
transcript tissue distribution of estrogen receptors alpha and
beta. Endocrinology 1997; 138(3): 863-70.

21.

Blair HC, Jordan SE, Peterson TG, Barnes S. Variable effects of
tyrosine kinase inhibitors on avian osteoclastic activity and
reduction of bone loss in ovariectomized rats. J Cell Biochem
1996; 61(4): 629-37.

22.

Anderson JJ, Anthony MS, Cline JM, Washburn SA, Garner SC.
Health potential of soy isoflavones for menopausal women. Public
Health Nutr 1999; 2(4): 489-504. Review.

23.

Watson CS, Pappas TC, Gametchu B. The other estrogen receptor
in the plasma membrane: implications for the actions of
environmental estrogens. Environ Health Perspect 1995; 103
(Suppl 7): 41-50.

24.

Gao YH, Yamaguchi M. Suppressive effect of genistein on rat
bone osteoclasts: involvement of protein kinase inhibition and
protein tyrosine phosphatase activation. Int J Mol Med 2000;
5(3): 261-7.

151

ÖZTÜRK TURHAN, N et al.

Effect of Isoflavones on Bone Mineral Density and Bone Turnover

Turk J Med Sci

25.

Mori M, Sagara M, Ikeda K, Miki T, Yamori Y. Soy isoflavones
improve bone metabolism in postmenopausal Japanese women.
Clin Exp Pharmacol Physiol 2004; 31 (Suppl 2): S44-6.

29.

Ettinger B, Genant HK, Steiger P, Madvig P. Low-dosage
micronized 17-estradiol prevents bone loss in postmenopausal
women. Am J Obstet Gynecol 1992; 166: 479–88.

26.

Camozzi V, Tossi A, Simoni E, Pagani F, Francucci CM, Moro L.
Role of biochemical markers of bone remodeling in clinical
practice. J Endocrinol Invest 2007; 30(6 Suppl): 13-7.

30.

Odell WE, Heath H. Osteoporosis: pathophysiology, prevention,
diagnosis, and treatment. Dis Mon 1993; 19: 789–98.

31.

27.

Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is
associated with higher bone mineral density in postmenopausal
but not premenopausal women. J Clin Endocrinol Metab 2001;
86(11): 5217-21.

Heaney RP, Gallagher JC, Johnston CC, Neer R, Parfitt AM,
Whedon GD. Calcium nutrition and bone health in the elderly. Am
J Clin Nutr 1982; 36 (5 Suppl): 986–1013.

32.

Dempster DW. Bone remodeling. In: Coe FL, Favus MJ, editors.
Disorders of Bone and Mineral Metabolism. 2nd ed. Philadelphia:
Lippincott Williams & Wilkins; 2002. pp. 315–44.

28.

152

Chiechi LM, Secreto G, D'Amore M, Fanelli M, Venturelli E,
Cantatore F et al. Efficacy of a soy rich diet in preventing
postmenopausal osteoporosis: the Menfis randomized trial.
Maturitas 2002; 42(4): 295-300.

